Our business has continuously experienced significant pressures on the pricing of our products and on our ability to obtain and maintain satisfactory rates of reimbursement for our products from governments, insurers and other payers… For example, in May 2025, the US administration issued an executive order aiming to implement “most‑favored‑nation” pricing tying US prescription drug prices with prices in selected comparably developed nations.
